본문으로 건너뛰기
← 뒤로

generation of dendritic cell vaccines in 3D printing scaffolds for cancer post-surgical therapy.

National science review 2026 Vol.13(5) p. nwag037

Chen L, Xu Y, Hu X, Pan Y, She P, Chen X, Peng Q, Li Q, Rao L

📝 환자 설명용 한 줄

Dendritic cell (DC) vaccines have shown great promise in cancer management, while complex cell culture limits their clinical applications.

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Chen L, Xu Y, et al. (2026). generation of dendritic cell vaccines in 3D printing scaffolds for cancer post-surgical therapy.. National science review, 13(5), nwag037. https://doi.org/10.1093/nsr/nwag037
MLA Chen L, et al.. " generation of dendritic cell vaccines in 3D printing scaffolds for cancer post-surgical therapy.." National science review, vol. 13, no. 5, 2026, pp. nwag037.
PMID 41710125
DOI 10.1093/nsr/nwag037

Abstract

Dendritic cell (DC) vaccines have shown great promise in cancer management, while complex cell culture limits their clinical applications. Here, we report an -generated scaffold DC vaccine, comprising a simple 3D-printed gelatin methacryloyl, bone marrow mononuclear cells (BM-MNCs), tumor lysates and stimulating factors. Stimulating factors in this vaccine effectively initiated differentiation of BM-MNCs into DCs, while personalized tumor lysates stimulated the maturation of differentiated DCs and enhanced their lymph node migration efficiency, thereby synergistically strengthening their antitumor effects. Moreover, the 3D hydrogel scaffold serves as an cell culture matrix, promoting the long-term viability of encapsulated cells and providing a conducive environment for BM-MNC differentiation and DC maturation within the surgical bed. In a prostate cancer post-surgical mouse model, the vaccine significantly inhibited tumor growth, suppressed tumor metastasis and extended median survival of animals to 55 days. This -generated DC vaccine bypasses cell culture, offering a simple, safe and robust strategy to elicit antitumor immunity for cancer treatment.

같은 제1저자의 인용 많은 논문 (5)